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Abstract: Overt response to a single 6.25 mg dose of ochratoxin A (OTA) by oral gavage 
to 15 months male rats was progressive loss of weight during the following four days. Lost 
weight  was  restored  within  one  month  and  animals  had  a  normal  life-span  without  
OTA-related terminal disease. Decline in plasma OTA concentration only commenced four 
days  after dosing,  while urinary excretion of OTA and ochratoxin  alpha  was  ongoing. 
During a temporary period of acute polyuria, a linear relationship between urine output and 
creatinine concentration persisted. Elimination of other common urinary solutes relative to 
creatinine  was  generally  maintained  during  the  polyuria  phase,  except  that  phosphate 
excretion  increased  temporarily. 
1H  NMR  metabolomic  analysis  of  urine  revealed  a 
progressive cyclic shift in the group principal components data cluster from before dosing, 
throughout  the  acute  insult  phase,  and  returning  almost  completely  to  normality  when 
tested six months later. Renal insult by OTA was detected by 
1H NMR within a day of 
dosing,  as  the  most  sensitive  early  indicator.  Notable  biomarkers  were  trimethylamine  
N-oxide and an aromatic urinary profile dominated by phenylacetylglycine. Tolerance of 
such a large acute insult by OTA, assessed by rat natural lifetime outcomes, adds a new 
dimension to toxicology of this xenobiotic.  
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1. Introduction  
Many acute and chronic dose-response studies have been made on ochratoxicosis in rats in past 
decades on account of the general and nephro-toxicity of ochratoxin A [1,2]. More recent advance in 
analytical methodology has facilitated more complex evaluations spanning exposure to ochratoxin A 
(OTA) over one or more days, or several weeks at doses that are generally sub-clinical in effect or are 
not markedly toxic [3–5]. In any case these exposures were several orders of magnitude greater than is 
the common extent of human dietary exposure, typically for example via agricultural cereals and their 
products and tropical spices, and occasionally via coffee and cocoa. Indirect exposure via pig kidney or 
liver can also occur. The possibility that the renal carcinogenicity of OTA in the rat could be a model 
for human risk of urinary tract malignancy has been a significant factor in food safety legislation. 
Whereas the NTP study [6] defined a dose range which was carcinogenic during lifetime exposure, the 
relative roles of exposure period and cumulative amount of carcinogen were unknown. Cumulative 
carcinogen dose has even been found to be a better exposure metric than daily dose [7]. The context of 
recent  EU-sponsored  studies  on  renal  carcinogenesis  by  OTA  [8,9]  has  provided  experimental 
opportunity also to demonstrate an obligatory period of 6–9 months exposure, only in the first year of 
male rat life [10], but also for the first time to follow outcomes after a single large oral dose of OTA 
for the rest of natural life. This is an exploratory step towards assessing a cumulative OTA exposure 
for rat renal carcinogenesis. Because of the long plasma half-life of OTA, a long cumulative period of 
renal exposure to the toxin might be expected from a single large dose, but such had not previously 
been explored. The findings, presently described, show the outcomes concerning pharmacokinetics and 
renal function, evolution of the urinary metabolomic profile through the immediate post-dosing phase 
and observations at necropsy. Since a quite marked, though tolerable, toxic impact was desired, mature 
adult males of the Fischer strain have been used instead of the young growing animals commonly used 
in toxicology studies. 
2. Materials and Methods  
2.1. Animal Experiment 
Three male Fischer rats, 15 months old (445, 486 and 517 g) had been caged together since supplied 
from B and K Universal Ltd., Grimston, Hull, and housed contemporary with the control group as 
previously described [8]. They were fed maintenance (14% protein) rat diet (Special Diet Services, 
Witham, Essex), and water, ad libitum. 
OTA (60 mg) was dissolved in ethanol (1 mL) and diluted with 4% sodium bicarbonate solution  
(4 mL). Rats were given 0.5 mL of the solution by oral gavage, in which therefore ethanol (100 µL) 
was also given. The solution was analysed quantitatively by HPLC with diode array detection [11] and 
found to contain 12.5 mg OTA/mL and 0.15 mg OTB/mL. Therefore the OTA dose administered to Toxins 2011, 3                         
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each animal was 6.25 mg. This was only a little above half of the published acute oral LD 50 dose for 
male rats [12] and was not intended to cause severe morbidity. All experimentation was conducted 
according to UK Home Office licence requirements. 
2.2. Histopathology 
Standard wax-embedded blocks were prepared from kidneys and all tumour tissues, and sections 
(3–4  µm)  were  stained  with  haematoxylin  and  eosin  in  the  Breast  Pathology  laboratory,  Guy‟s 
Hospital, London. 
2.3. Urinalysis 
Automated urinalysis for creatinine, protein, calcium, sodium, potassium, urate, urea and phosphate 
was performed in the Chemical Pathology Laboratory at St. Mary‟s Hospital, Paddington, London, 
using an Olympus AU640 instrument with methodology described in [13].  
2.4. Analysis of Ochratoxin A in Rat Plasma 
Measurement of the concentration of OTA in rat plasma was contracted to the standardised and 
validated protocol at the Central Science Laboratory, York, UK. The limit of measurable detection was 
<0.1 µg/mL, which takes into account the considerable dilution of most of the samples to be in the 
usual range for HPLC analysis. Samples came from only 200 µL of blood, withdrawn from a tail vein 
under general anaesthesia, from which plasma was immediately separated (eppendorf centrifuge) and 
stored at −20 ° C. The analytical protocol, immuno-affinity cartridge clean-up followed by HPLC with 
fluorescence detection, was as previously described [14,15]. 
2.5. Measurement of Ochratoxin A in Rat Urine 
The quantity of OTA present in each urine sample was assessed by addition of a known quantity of 
authentic  standard,  as  given  to  the  rats  and  used  elsewhere  [3],  with  measurement  via  
ultra-performance liquid chromatography-mass spectrometry (Waters Acquity and LCTpremierMS) 
with a stepwise linear gradient. A 20 µL sample was injected onto a C18 BEH Acquity column and 
separated using a mobile phase of water plus 0.1% formic acid (solvent A) and acetonitrile plus 0.1% 
formic acid (solvent B). The LC run was isocratic up to 1.5 min with mobile phase of 0.5% B, followed 
by gradient elution (column temperature was 40 ° C). The gradient was 1.5–5 min, 0.5–30% B; 5–15 min, 
30–70%  B;  15–18  min,  70–99.5%  B;  18–20  min,  99.5–0.5%  B.  At  all  stages  the  flow  rate  was  
0.5 mL/min and the data were acquired in positive mode. Measurement of the integral of the OTA 
peak was made of the sample before and after spiking with a known concentration of standard and the 
total urinary concentration was calculated from relative intensity of the m/z 404.089 parent ion eluting 
at 9.3 min.  
2.6. Measurement of Ochratoxin Alpha in Rat Urine 
The quantity of ochratoxin alpha present in the 8–25 h urine sample from Rat B was assessed by 
addition of a known quantity of authentic standard (courtesy of H. Zepnik, University of Wuertzburg) Toxins 2011, 3                         
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with measurement via high-performance liquid chromatography-mass spectrometry (Waters Aliance 
2795 and QToFmicro). A 10 L sample was injected onto a C18 Symmetry column and separated using 
a mobile phase of water plus 0.1% formic acid (solvent A) and acetonitrile plus 0.1% formic acid 
(solvent  B).  The  LC  run  was  isocratic  up  to  0.5  min  with  mobile  phase  of  100%  A,  followed  
by  gradient  elution  (column  temperature  was  40  ° C).  The  gradient  was  0.5–4  min,  0–20%  B;  
4–8 min, 20–95% B; 8–9 min, 95–95% B; 9–9.1 min, 95–0% B. At all stages the flow rate was  
0.6  mL/min  and  the  data  were  acquired  in  negative  mode.  The  total  urinary  concentration  was 
calculated from relative intensity of the m/z 255.006 parent ion eluting at 5.8 min. 
2.7. 
1H NMR Spectroscopic Analysis of Whole Rat Urine 
Each  sample  (400  µL)  was  mixed  with  200  µL  of  phosphate  buffer  (0.2  M  NaH2PO4:  0.2  M 
Na2HPO4 (19:81), pH 7.4). Aliquots of the resulting mixture (500 µL) were placed in 5 mm NMR 
tubes to which 50 µL of a solution of TSP in D2O was added (final concentration, 1 mM). The D2O 
plus TSP addition provided both a chemical shift reference (δ0.0) and a field frequency lock signal. 
One-dimensional  (1D) 
1H  NMR  spectra  were  acquired  at  600.13  MHz  on  a  Bruker  DRX-600 
spectrometer  using  a  standard  pre-saturation  pulse  sequence  for  water  suppression  with  solvent 
irradiation in the relaxation delay (3 s) and the mixing time (100 ms). NMR spectra were acquired 
using 256 scans into 64 k points with a spectral width of 9615 Hz, an acquisition time of 3.4 s, and a 
total pulse recycle delay of 6.25 s. The FIDs were multiplied by an exponential function corresponding 
to a 0.3 Hz line broadening prior to Fourier transformation (FT). All data were phased and baseline 
corrected manually in TopSpin (version 2.5, Bruker GmbH, Germany). 
2.8. Multivariate Statistical Analysis of 
1H NMR Spectral Data 
All NMR spectra were processed for multivariate statistical analysis using the AMIX software 
(version  3.9.7,  Bruker  GmbH,  Germany).  The  spectra  were  normalised  to  the  total  integral  
(excluding water, urea and TSP) and data reduced to a series of 0.02 ppm integrated regions for 
analysis.  The  reduced  dataset  was  pre-processed  (pareto  scaling)  and  analysed  via  Principal 
Components Analysis (PCA) and Partial Least Squares-Discriminant Analysis (PLS-DA) using the 
SIMCA-P+ software package (version 11.5, Umetrics, Umea, Sweden). Initial data analysis focused 
on comparison of the data from all samples to determine the time-periods of effect and recovery. 
Subsequently individual comparisons of the loadings data from the pre-dose samples were made 
with  each  of  the  post-dose  sample  groups  to  determine  the  specific  endogenous  metabolites  
differing at each time-period. Assignment of the NMR spectral resonances highlighted from this 
analysis were made based on SBASE2.0 (Bruker GmbH, Germany) and online resources [16]. 
3. Results 
3.1. The Acute Toxicity Phase 
After administration of OTA rats lost ~10% of body mass during the next 3–4 days (Figure 1), but 
after 4 days the lost mass was gradually recovered during the following month. Since rats were in 
metabolism cages for 18 h on days 1, 3 and 4 and were anaesthetised briefly for blood sampling six Toxins 2011, 3                         
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times during the period of mass loss, albeit always with access to feed and water ad libitum, it is not 
possible  to  distinguish  between  these  experimental  factors  and  any  other  direct  toxicity-based 
inappetence in causing the loss. 
Figure  1.  The  course  of  change  in  mean  rat  weight  during  the  month  after  an  acute  
6.25 mg OTA dose, showing sharp recovery after four days of weight loss. 
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Absorption  efficiency  of  intestinal  OTA  was  indicated  by  achievement  of  maximum,  or  near 
maximum, plasma concentration measured 7 h after dosing. Concentration values in the 50 µg/mL 
range were maintained in all animals during the following 4 days (Supplementary data, Figure 1) and 
the pattern over a month is shown in Figure 2. Assuming plasma volume represented ~4% of body 
mass in these mature males, OTA in the total vascular compartment accounted for only ~10–15% of 
that administered. Six months later, OTA in the urine output during 18 h overnight was measured at 
5.2 µg (± 0.8 µg), demonstrating that the toxin was still in the blood in amounts greater than the trace 
level that might be acquired from commercial rat diet. In the intervening period, the pattern of plasma 
OTA concentration decline was similar in all animals (Figure 2). Log mean values at the various time 
points plotted against time (Supplementary data, Figure 2) show the decline more clearly, and its linear 
shape which fits a plasma half-life of ~9 days that is close to that measured in animals receiving  
long-term dietary exposure to OTA [15]. 
Polyuria became evident on days 3 and 4 (Table 1) and was the only overt indicator of toxicity. 
Urinalysis showed that creatinine concentration was correlated with polyuria. Plotting urine output 
against creatinine concentration showed a consistent linear relationship in all animals (Supplementary 
data,  Figure  3)  indicating  an  OTA  effect  on  water  retention  in  the  distal  part  of  the  nephrons. 
Expression  of  concentration  of  other  urinary  parameters  relative  to  excretion  of  one  mmole  of 
creatinine (Table 1)  revealed no consistent  pattern of  marked changes  for calcium, urate, protein, 
sodium or potassium. However, increase in phosphate excretion through the four days post-dosing may 
be a significant temporary change, but phosphate excretion had reverted to the pre-dosing status when Toxins 2011, 3                         
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measured again six months later. Urinalysis findings one year after dosing in one rat (rat A, Table 1) 
are  notable  only  for  much  elevated  excretion  of  calcium,  protein  and  phosphate  in  this  ageing  
(21 month old, but not leukaemic) animal.  
Figure  2.  Plasma  OTA  concentration  at  intervals  for  individuals  during  the  month 
following a 6.25 mg OTA dose to three adult male Fischer rats. 
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Table 1. Urinalysis data (± SD) for 18 h collections from rats at intervals after gavage 
dosing of 6.25 mg OTA. Units; volume (mL), creatinine (mmol/L), and other parameters 
(mmol/mmol creatinine). 
  Volumes  Creatinine  Calcium  Urate  Protein  Na  K  PO4  Urea 
Pre-OTA  7.5 
(2.60) 
10.63 
(2.65) 
0.31 
(0.02) 
0.12 
(0.04) 
0.40 
(0.16) 
7.54 
(3.18) 
19.45 
(4.62) 
2.28 
(0.77) 
87.39 
(6.79) 
8–25 h  7.17 
(1.04) 
9.18  
(0.98) 
0.33 
(0.09) 
0.2 
(0.05) 
0.39 
(0.16) 
12.32 
(4.77) 
12.83 
(2.03) 
3.55 
(1.40) 
77.27 
(0.67) 
55–74 h  15.8 
(10.37) 
6.50  
(3.94) 
0.18 
(0.11) 
0.2 
(0.15) 
0.42 
(0.12) 
11.67 
(2.24) 
12.66 
(0.82) 
5.56 
(0.68) 
60.14 
(2.02) 
79–88 h  30.7 
(2.87) 
2.29  
(0.13) 
0.13 
(0.09) 
0.1 
(0.02) 
0.63 
(0.07) 
7.03 
(1.79) 
18.76 
(2.05) 
4.41 
(1.02) 
58.00 
(1.82) 
6 months  7.97 
(1.56) 
10.55 
(1.96) 
0.27 
(0.11) 
0.17 
(0.02) 
0.37 
(0.23) 
3.39 
(1.20) 
14.93 
(1.46) 
2.64 
(0.40) 
61.44 
(1.64) 
12 months  14.5  4.66  1.28  0.34  3.04  10.33  22.27  6.19  52.56 
Measurement of OTA  excreted in urine during 18 h periods at intervals early in the experiment 
(Figure 3) showed significant output during the first day for all animals. Thereafter on days 3 and 4 a 
similar situation generally prevailed except for a higher value on day 3 for one rat. While the analytical 
method was not officially validated for quantitative purposes, its reliance on ion current from a specific 
OTA MS fragment at least makes quantification relative to an OTA standard meaningful within the 
group of urines analysed.  Toxins 2011, 3                         
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Sensitive and specific urinalysis for ochratoxin alpha, with limit of detection at ~300 fg/µL enabled 
measurement  in  the  urine  of  rat  B  excreted  during  the  8–25  h  post-dosing  period  as  10.2  µg, 
representing 0.3% of the OTA given. 
Figure 3. Urinary 18-h output of OTA before and during the four days after a 6.25 mg oral 
dose to three adult male rats. 
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3.2. Survival and Necropsy 
Survival for 23, 25 and 27 months (Supplementary data, Figure 4), is within the normal lifetime 
range for Fischer male rats. Rat A was euthanized somewhat prematurely due to a facial abscess, but 
there were no obvious internal abnormalities and no tumours were found in kidneys. Rat B developed 
leukaemia, confirmed by the splenomegaly (16 g) and mottled liver found at necropsy, but there was 
no renal histopathological change atypical for an old rat. Rat C was also leukaemic (spleen 16.7 g, 
spongy liver); kidneys were not abnormal in size or colour and contained no tumour, but testes had 
atrophied. 
3.3. Metabolomics 
Principal  component  analysis  data,  from  comparative  analysis  of 
1H  NMR  spectra,  is  plotted 
graphically  for  individual  animals  for  the  five  sampling  stages  including  pre-dose  and  6  months  
post-dose (Figure 4). Clustering of data from the three rats at the various stages progressed through 
distinct distance shifts along a cyclic pattern which eventually, after 6 months, had returned to the  
pre-dose  status,  thus  demonstrating  both  kinetics  of  the  toxic  insult  and  its  apparently-complete 
eventual resolution. Toxins 2011, 3                         
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Figure  4.  PC1  vs.  PC2  scores  plot  of  the  NMR  data  from  the  three  rats  over  the  
time-course of the study. 
 
Examples of spectra showing the different patterns of urine components through the toxic insult, 
and later to recovery, are given as a stack plot in Figure 5, representing all samples from Rat A, which 
exhibited the least severe polyuria during the 79–98 h collection period. The spectra are normalised to 
the total integral of the displayed region. Notably, all three rats had a similar pattern of weight loss 
through the four days after dosing, illustrated in the body weight data in Figure 1. The stacked data in 
Figure 5 are therefore a conservative illustration for the whole group. The compounds which showed 
notable change in  urine through the study, as  identified from  the statistical  analysis, are listed in  
Table 2. The small amount of ethanol in the OTA dose vehicle was undetectable. 
Specifically and chronologically, in the 8–25 h post-dose period hippurate virtually disappeared as a 
urine component and only reappeared in the 6 month sample. Phenylacetylglycine was a significant 
temporary  component,  but  had  become  virtually  absent  three  days  later.  Trimethylamine-N-oxide 
(TMAO) was also a prominent new component, recognised as additive to a taurine resonance, but then 
could not be detected by 79–98 h. New signals from an unassigned metabolite were also observed at  
δ7.47 (t) and δ7.34 (t). 
Analysis  of  the  loadings  influencing  differentiation  of  the  predose  urine  samples  from  those 
collected at 55–74 h indicated that the affects observed post-dose were dominated by an elevation in 
citrate,  2-oxoglutarate, succinate, allantoin and  creatinine. Changes  evident  as  decreased  excretion 
were  taurine,  trimethylamine-N-oxide  and  hippurate,  but  by  79–98  h  further  diminution  of  their 
resonances was observed. 
The temporal shift from the pre-dose and 8–25 h post-dose periods through to the 79–98 h period 
was due to a glycosuria, aminoaciduria (principally concerning glutamine) and lactic aciduria coupled 
with  reduced  hippurate  and  citrate  concentration.  Reduced  signal  intensities  were  consistent  with 
marked polyuria in all animals (Figure 5). Toxins 2011, 3                         
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Figure 5. Stack plot of NMR spectra for rat B, pre-dose, after one, three and four days, and 
after six months. Spectra are representative of the three rats. 
 
Table 2. Endogenous metabolites affected by administration of Ochratoxin A. 
Metabolite 
Time-Period 
of Change 
Delta 
Hippurate  8–25  decrease 
Phenylacetylglycine  8–25  increase 
TMAO  8–25  increase 
Citrate  55–74  increase 
2-Oxoglutarate  55–74  increase 
Succinate  55–74  increase 
Allantoin  55–74  increase 
Creatinine  55–74  increase 
Taurine  55–74  decrease 
TMAO  55–74  decrease 
Hippurate  55–74  decrease 
Glucose  79–98 h  increase 
Glutamine  79–98 h  increase 
Lactate  79–98 h  increase 
Hippurate  79–98 h  decrease 
Citrate  79–98 h  decrease Toxins 2011, 3                         
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4. Discussion  
Our study uniquely demonstrates a remarkable recovery in renal function after a relatively large 
acute dose of OTA, implying that the insult had not caused profound structural damage and that renal 
carcinogenicity of the toxin operates via sub-clinical influences during the necessary exposure period 
of several months in the first year of life [10]. The eight day plasma half-life of OTA in these Fischer 
rats, being shorter than the ten day value measured when chronic OTA exposure ceases [15], at least 
indicates  that  no  significant  perturbation  of  renal  function  or  long-term  health  problem  persisted 
beyond the four days of post-dose morbidity. Ultimate tolerance of the maximum OTA that might 
safely be given was evident as rats regained their lost weight (presumably via lipid reserves). From 
previous experience [17], the present dose would not have been consumed if given in feed, implying 
an intrinsic effect of high dose of OTA on appetite. Animals lived into the normal life span for the 
Fischer strain and presented no unexpected pathology at necropsy other than is typical in aged rats. 
Notably no macroscopic or microscopic neoplasms were evident in kidney or in testis. Polyuria has 
also been reported after 7 and 21 days of OTA exposure (500 µg/kg/day) [18]. The single OTA dose 
here represented an amount equivalent to the cumulative daily intake that would be necessary during  
~250 days to cause at least a 5% incidence of renal cell carcinoma [9]. Thus in the present experiment 
an acute OTA dose of ~40 mg might have been necessary to represent the cumulative requirement for 
a high incidence of renal carcinoma if delivered during a similarly protracted period. Predictably, that 
acute dose would have been lethal. A single OTA dose of 1 mg to Fischer rats caused a simple pattern 
of covalent DNA adducts in kidney [19], confirming exposure to the carcinogen, but that finding alone 
could not logically predict carcinogenesis without corresponding evidence that the long obligatory 
period of repeated insults with the toxin had occurred. Further, the present rats were exposed to OTA 
only in their second year of life, during which Fischer male rats have demonstrated much less response 
to carcinogenicity of OTA [20]. However, at least renal adenoma could have been expected from 
exposure in second year. Nevertheless, for at least a month, OTA was circulating in the present rats at 
a concentration in plasma above that which is potentially able to cause rat renal tumours if continued 
for about 9 months [10,15]. Thus the present findings can be a step towards experimental verification 
of the extent to which cumulative OTA exposure could be a predictor of cancer [21] in a rat model. 
The maximum amount of OTA circulating in the vascular compartment during the first day in the 
present experiment (~1 mg) accounts for only ~15–20% of the given dose, but this was contemporary 
with typical renal excretory function as indicated by detection of both OTA and ochratoxin alpha in the 
urine. In [22] ochratoxin alpha was measured as the principal urinary metabolite of OTA, eventually 
accounting for about 25% of the mycotoxin administered parenterally once, and therefore the present 
finding  confirmed  typical  OTA  metabolism  occurring  through  the  period  of  uptake.  It  was  also 
established [4] that OTA excretion in urine increased steadily over two weeks of dosing, though with 
dosing  only  on  five  consecutive  days  each  week,  in  a  dose-dependent  and  proportionate  way. 
However, an interesting concomitant pattern in two separate cycles of excretion of ochratoxin alpha [4] 
indicated a profound change in OTA metabolism kinetics in kidney as soon as the first dosing period 
ended, while OTA concentration in the plasma circulating through the organ was well maintained. 
The present experiment extends the direct relationship in Fischer rats between single dose amount, 
e.g., 0.5 mg/kg body weight [3,23,24] and maximum plasma concentration (~2 µg/mL), by showing Toxins 2011, 3                         
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here that a 25-fold increase in dose gave a mean plasma concentration of ~50 µg/mL. Also, the present 
single OTA dose was ~60-fold greater than that of the “lifetime” high-dose regimen in the classic NTP 
study [6], and allowed plasma OTA concentration to remain for ~35 weeks above that(1–2 µg/mL) 
associated with causing a very low incidence of renal cancer when given throughout life [9]. 
Notably in [24], quicker OTA uptake was shown in fasted adult males than fed males in the first 
two  hours,  and  achieved  double  the  plasma  concentration  (Figure  6).  Presumably  OTA  had  been 
mostly bound to plasma proteins in both situations.  It is no surprise that this could not easily be 
explained when so little is known about the kinetic fate of OTA molecules after entering the blood 
compartment  and  being  subject  to  competition  of  protein  binding  of  the  15–20%  minority,  and 
distribution of the remaining majority throughout the body. Far from just being unexplained, the robust 
analytical findings [24] could be reflecting the profound qualitative and quantitative changes in plasma 
proteins through puberty in male rats, as evidenced at least by those that escape to become the major 
group of urinary proteins which are becoming of increasing biological interest [25]. 
Figure  6.  Expansion  of  mean  plasma  OTA  measurements  during  the  two  hours  
post-dose in fed and fasted male Fischer rats showing the contrasting rates of uptake 
(after Vettorazzi et al. 2010). 
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In the study with male Fischer  rats in early puberty [4], conducted with exactly the same OTA 
material as here (cited purity 99.9%), metabolomic urinary changes were detected after two weeks of 
gavage treatment with OTA (1 mg/kg), but became more apparent at twice that dose. The highest daily 
dose (2 mg/kg), six-fold less than used presently, impaired growth slightly, but caused progressively 
greater polyuria. Aromatic amino acids were recognised only in the day after the first dose. However, 
trimethylamine N-oxide was already strikingly apparent 2 h after the first dose, declining in intensity 
thereafter but still evident after two weeks of treatment. Trimethylamine N-oxide concentration decline 
was  in  spite  of  continued  dosing,  which  elevated  plasma  OTA  concentration  ~50-fold  during  the 
period. Subsequently, it was confirmed [5] that, during 13 weeks of exposure, the low OTA doses as 
tested [4] did not cause excretion of trimethylamine N-oxide. It was suggested that this was a specific 
toxicological feature of OTA. However, the present excretion of trimethylamine N-oxide just in the first Toxins 2011, 3                         
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day after dosing, in spite of very high plasma OTA concentration persisting thereafter, implies that this 
biomarker may occur in kidney as a shock response to OTA. Occurrence of trimethylaminuria was 
regarded [26] as a defect in detoxication, whereas it was originally proposed [27] that the metabolite was 
an  indicator,  at  least  also  in  Fischer  rats,  of  site-specific  renal  papillary  injury  concomitant  with 
polyuria, as can be caused by propylene imine. If OTA renal toxicology elicits a similar response at 
first exposure, it seems to happen 2–3 days before polyuria becomes manifest. It is not clear whether 
polyuria is due to direct interaction with the toxin in collecting ducts or through more distant adrenal or 
pituitary influence. 
Metabolomic change in the first day following the OTA dose characterised by phenylacetylglycine 
excretion  is  reminiscent  of  response  of  germ-free  rats  to  transfer  to  a  conventional  housing 
environment [28]. Although urinary tricarboxylic acid cycle intermediates have been shown to  be 
affected by reduced food consumption [29], this is normally manifest as a reduction. The compounds 
which  were  elevated  here  have  also  been  similarly  elevated  in  animals  that  exhibit  an  idiopathic 
susceptibility to developing a renal toxic response following cisplatin administration [27]. As with 
OTA, cisplatin‟s target for histopathological change is the pars recta region of nephrons.  
Overall in the acute phase, the elevated urinary citrate and hippurate most probably reflected an 
induced mild anorexia resulting in lower availability of TCA intermediates (hence reduced urinary 
citrate) and a stressor to the intestinal gut microflora (the principal contributor to urinary hippurate). 
The increase in markers of tubular damage in the kidney, assessed from considerable background 
experience of 
1H NMR spectroscopy-based metabolomic assessment of toxicity [30,31], indicated that 
by the 79–98 h post-dose stage an adverse event was manifest in the organ. However, weight gain in 
all animals resumed a day later (Figure 1) implying both improved appetite and recovery of efficient 
medullary regulation of urinary output volume. 
The present findings challenge current understanding about distribution and transport mechanisms, 
and raise questions about pharmacokinetics of OTA. OTA given via a jugular vein followed kinetics of 
immediately–declining plasma values in mature female Sprague-Dawley rats [32], showing a 4-day 
half-life after injecting 100 µg in aqueous vehicle. This route avoided the complexities of intestinal 
uptake and focused just on the rate of elimination. OTA (~125 µg) was given in corn oil by oral 
gavage to Fischer males [3]; the toxin had a longer plasma half life (9 days) in this rat strain. More  
recently  [20],  repetitive  dosing  in  mature  adult  males  took  a  month  to  reach  maximum  plasma 
concentration.  Use  of  the  „five-days-a-week  oral  gavage  in  an  oil  vehicle‟  protocol  of  the  NTP  
study [6] during two weeks [4], followed a similar pattern in young males. 
Fischer rats have also been used [23,24] to focus on intestinal absorption in fed and fasted rats after 
single oral gavage dose of ~100 µg OTA in aqueous vehicle. Decline in plasma OTA concentration 
was already evident within one day of dosing. Notably also, gender difference in pharmacokinetics 
was found, but only in 15-week fed rats in which males achieved the significantly lower CMAXobs 
value  initially.  The  present  protocol  resembled  the  findings  in  [23]  but  with  a  greatly  increased  
(25-fold) dose and a design which studied all animals thereafter for life. Decline in plasma OTA 
concentration was delayed for four days (Supplementary data, Figure 1) but thereafter, during the  
day  7  to  day  28  period,  the  decline  in  log  concentration  of  OTA  in  plasma  followed  a  linear 
configuration when plotted against time (Figure 2), equating to a half-life value of eight days. It is 
assumed that there was considerable flux between the OTA initially distributed widely in tissues and Toxins 2011, 3                         
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that which entered the vascular compartment. The plasma concentration achieved during the first day 
demonstrated  a  proportional  relationship  with  the  oral  dose  over  a  wide  dose  range.  Early 
establishment of excretion of OTA and its metabolite ochratoxin alpha allows conjecture about the 
mechanism of clearance from tissue into blood, the identity of plasma proteins with which the toxin 
binds competitively in vivo, the mechanism(s) and kinetics of competitive interactions, and the way(s) 
in which OTA that is mostly protein-bound in plasma is eliminated via nephrons. We perceive that 
what happens after an acute dose may not be the same as when plasma concentration stabilises after a 
month  of  continuous  ingestion  of  OTA,  otherwise  plasma  accumulation  could  hardly  occur. 
Maintenance of a steady state concentration in plasma is very sensitive to cessation of OTA uptake 
[10,15], implying some metabolic adaptation during continuous exposure to OTA. The extent of rat 
plasma proteins to which OTA binds  in  vivo is unknown. Although binding to  albumin has been 
modelled, no X-ray crystallographic data has apparently yet been presented; indeed, repeated attempts 
to obtain a crystal with a cloned human serum albumin at Imperial College London have unfortunately 
failed (with P. Zunszain and S. Curry). The extent of vascular involvement of OTA with male-rat 
urinary lipocalins, with short half-life in blood because they easily pass with glomerular filtrate, is 
unknown. From the literature, it is also difficult to have a clear picture of the dynamics of transport in 
kidney from blood to nephron epithelia and ultimately into urine. For example, a recent review [33] 
has excluded glomerular filtration of free OTA because of a classical reference to the strong binding of 
OTA to plasma protein. Consequently a complex scenario is proposed based on several in vitro studies 
on organic anion transporters, which offers explanation for accumulation of OTA in kidney. However, 
there was no recognition that protein binding of the phenylalanine derivative OTA is not irreversible 
and that the easiest exit of free toxin, maintained in blood at ~2% of plasma OTA by the principles of 
dissociation, is via glomerular fenestrations, as applies also to its analogue phenylalanine. 
Further,  the  popular  belief  that  OTA  accumulates  in  rat  kidney  is  mostly  an  illusion,  since 
researchers persist in ignoring the OTA in the large vascular compartment which accounts for at least 
most of kidney OTA. Thus, in [3], although kidney was flushed with saline by hypodermic syringe 
inserted into the renal artery immediately after excision, it can be calculated that the OTA measured in 
blood plasma could have accounted for all OTA in kidney if only a residual 10% plasma component 
remained. Predictably, such flushing could not remove blood from peri-tubular vasculature without the 
benefit of blood pressure to keep vessels open [34]. Similar calculation can be made concerning other 
studies  [4,35],  based  on  the  elegant  computerised  tomography  [34].  The  same  could  apply  to  
OTA-DNA adducts in vascularised tissues, if the adducts also occur in blood. 
During two weeks of gavage administration of OTA in corn oil to young Fischer male rats [4], 
mimicking the five days a week dosage regimen used in the NTP study [6], dose-related accumulation 
of OTA in plasma was recorded, and dose-related similar concentration in flash-frozen kidney and 
liver at the end of the experiment. Unfortunately, involvement of OTA in the proportionately large 
vascular compartment of both organs, which would have accounted for most or all of the organs‟ OTA, 
was not recognised. For example, at 2 mg OTA/kg body weight, a plasma concentration of 40 µg/mL 
was achieved. OTA was measured in kidney as 3.2 µg/g, but plasma in the vascular compartment 
would have potentially contributed ~6 µg OTA/g tissue. Similarly when dosed at 1 mg OTA/kg, the 
ensuing plasma OTA content of 17 µg/mL would have contributed more than the OTA measured in 
tissues. Another study [17], also measuring OTA in plasma, kidney and liver, quotes plasma values Toxins 2011, 3                         
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after 7 and 21 days of daily dosing which account for all OTA in kidney and liver of Fischer male rats, 
assuming organ plasma composition only in the ranges 7.5–8% and 8.5–10%, respectively. 
Such  considerations  might  only  be  of  academic  significance  if  OTA  and  its  toxicity  did  not 
command  extensive  scrutiny  and  legislation  for  food  safety  [1,2].  Yet,  while  no  case  of  human 
ochratoxicosis  has  been  established,  there  remains  poor  understanding  of  uptake  and  excretory 
mechanisms  in  the rat,  which has  been the principal experimental toxicological  model for human 
kidney disease. The latter is typically focused towards the mainly idiopathic incidence of renal cell 
carcinoma as a global malignancy, and the regionally-specific Balkan endemic nephropathy with its 
characteristic bilateral renal atrophy and the urinary tract tumours that sometimes also occur. Even 
lifetime exposure to OTA does not cause renal atrophy or urinary tract tumours in rats. Fairly high 
intake of OTA over many months can cause carcinomas in renal parenchyma, but molecular work in 
progress points more towards analogy with the spontaneous renal tumours of the Eker rat than to 
humans. Thus for defining fundamentals in human disease aetiology and in making correct attribution 
of xenobiotic toxins in food safety it is regrettable that so little is known about OTA in vivo. 
Further experimental definition of the OTA exposure criteria (e.g., dose vs. frequency vs. duration) 
necessary for causing the renal genetic damage necessary for carcinogenesis would greatly assist in 
moving toward a more enlightened and objective attitude to OTA as a mycotoxin of potential concern 
for  human  health.  Greater  understanding  of  male  rat  pharmacokinetics  through  the  carcinogenetic 
period would assist in making a valid model for human risk. 
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